Thermo Fisher Scientific Inc. (NYSE:TMO) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Thermo Fisher Scientific has an average analyst rating of “Moderate Buy” from 24 analysts, with 18 buy ratings and 2 strong buy ratings. The average 12-month target price is about $613.67.
• The company recently reported better-than-expected quarterly results, posting EPS of $5.44 versus estimates of $5.25 and revenue of $11.01 billion versus expectations of $10.86 billion. Revenue rose 6.2% year over year.
• Shares fell 2.2% to $483.13, even as institutional ownership remains high at 89.23%. The company also declared a quarterly dividend of $0.47 per share, payable July 15.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twenty-four analysts that are covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation, eighteen have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $613.6667.

A number of equities research analysts have weighed in on TMO shares. Barclays reduced their target price on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating on the stock in a report on Tuesday, April 14th. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 target price on the stock. Royal Bank Of Canada set a $490.00 target price on shares of Thermo Fisher Scientific and gave the stock a "sector perform" rating in a report on Thursday, May 14th. Stifel Nicolaus reduced their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a "buy" rating on the stock in a report on Friday, April 24th. Finally, DZ Bank started coverage on shares of Thermo Fisher Scientific in a report on Friday, March 27th. They set a "buy" rating and a $610.00 target price on the stock.

Insider Activity at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares of the company's stock, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company's stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

A number of institutional investors have recently modified their holdings of TMO. J. Stern & Co. LLP boosted its stake in shares of Thermo Fisher Scientific by 58,006.4% in the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock valued at $18,258,082,000 after purchasing an additional 31,455,105 shares during the last quarter. Norges Bank bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $3,072,744,000. Auto Owners Insurance Co boosted its stake in shares of Thermo Fisher Scientific by 57,845.0% in the 4th quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company's stock valued at $1,406,844,000 after purchasing an additional 2,423,706 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in shares of Thermo Fisher Scientific by 2,183.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,328,845 shares of the medical research company's stock valued at $770,000,000 after purchasing an additional 1,270,643 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in shares of Thermo Fisher Scientific by 88.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company's stock valued at $1,309,292,000 after acquiring an additional 1,270,191 shares during the period. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Trading Down 2.2%

Shares of Thermo Fisher Scientific stock opened at $483.13 on Thursday. The firm has a market capitalization of $179.54 billion, a PE ratio of 26.56, a price-to-earnings-growth ratio of 2.19 and a beta of 0.88. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The firm's 50 day moving average is $480.02 and its 200 day moving average is $528.89. Thermo Fisher Scientific has a 1 year low of $385.46 and a 1 year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. During the same period in the previous year, the firm posted $5.15 EPS. The firm's revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities research analysts forecast that Thermo Fisher Scientific will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be given a $0.47 dividend. The ex-dividend date is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.